Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdAltaASX:1AD 3-Year EBITDA Growth Rate is 27.00% as of Dec. 2025, which is 9% above its 10-year median of 24.85. The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, AdAlta ranks better than 62.95% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of AdAlta was 35.20% per year. The lowest was 11.60% per year. And the median was 24.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AdAlta 3-Year EBITDA Growth Rate Related Terms
ASX:1AD vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, AdAlta's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AdAlta 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AdAlta's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AdAlta's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.00% mean?
AdAlta (ASX:1AD) has a 3-Year EBITDA Growth Rate of 27.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AdAlta and its competitors. This is near median its historical median of 24.85. Over the past decade, AdAlta's 3-Year EBITDA Growth Rate has ranged from 11.60 to 35.20. According to the industry distribution chart, AdAlta ranks #419 out of 1131 companies in the Biotechnology industry, placing it in the top 37%.
Is AdAlta's 3-Year EBITDA Growth Rate too high?
AdAlta's current 3-Year EBITDA Growth Rate of 27.00% is near median its 10-year median of 24.85. Over the past 10 years, this metric has ranged from a low of 11.60 to a high of 35.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. AdAlta's value of 27.00% is 81.2% above this industry median. Based on the distribution chart, AdAlta ranks #419 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint.
How does AdAlta's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AdAlta ranks #419 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts AdAlta in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. AdAlta's value of 27.00% is 81.2% above this benchmark. Historically, AdAlta's own 3-Year EBITDA Growth Rate has ranged from 11.60 to 35.20 over the past decade. While the company's 10-year median is 24.85 vs. the industry median of 14.90, AdAlta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AdAlta's current 3-Year EBITDA Growth Rate of 27.00% is 81.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AdAlta and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AdAlta's current 3-Year EBITDA Growth Rate is 27.00%, which is near median its own 10-year median of 24.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AdAlta stock overvalued right now?
AdAlta (ASX:1AD) has a current 3-Year EBITDA Growth Rate of 27.00%. The current 3-Year EBITDA Growth Rate is 27.00%, which is near median its 10-year median of 24.85 and 81.2% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AdAlta (ASX:1AD), the current 3-Year EBITDA Growth Rate is 27.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AD has been successfully added to your 
